

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1543

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/402,820
		Filing Date	October 12, 1999
		First Named Inventor	CHAIN, Daniel G.
		Group Art Unit	1543
		Examiner Name	P. Duffy
Sheet 1 Of 2	Attorney Docket Number	P-4815-US	

RECEIVED
MAY 23 2002

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PAO		BUSCIGLIO J, ET AL. (1193) "Generation of b-amyloid in the secretory pathway in neuronal and nonneuronal cells" Proc. Natl. Acad. Sci. 90, 2092-2096	<input type="checkbox"/>
PAO		GEDDES JW ET AL. (1999) "N-terminus truncated b-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease" <i>Neurobiol of Aging</i> 20, 75-79.	<input type="checkbox"/>
PAO		HAAS C ET AL. (1992) "Amyloid b-peptide is produced by cultured cells during normal metabolism" <i>Nature</i> 359, 322-325	<input type="checkbox"/>
PAO		HAAS C ET AL. (1993) "Cellular processing of β amyloid precursor protein and the genesis of amyloid β -peptide." <i>Cell</i> 75, 1039-1042	<input type="checkbox"/>
PAO		HIGGINS LS ET AL. (1996) "p3 b amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain." <i>Am. J. Pathol</i> 149, 585-596	<input type="checkbox"/>
PAO		JOHNSON-WOOD K. ET AL. "Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease" <i>Proc Natl. Acad. Sci U.S.A.</i> 1997 Feb 18;94 (4): 1550-5	<input type="checkbox"/>
PAO		LALOWSKI M (1996) "The nonamyloidogenic p3 fragment (amyloid β 17-42) is a major constituent of Down's syndrome cerebellar preamyloid." <i>J Biol Chem</i> 271, 33623-31	<input type="checkbox"/>
PAO		LARNER AJ (1999) "Hypothesis: amyloid b peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease." <i>Neurobiol. Of Aging</i> 20, 65-69.	<input type="checkbox"/>

RECEIVED
MAY 20 2002
TC 1700

15

Please type a plus sign (+) inside this box →

MAY 16 2002

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

MAY 23 2002

RECEIVED

PAO	MASTERS CL ET AL. (1985) "Amyloid plaque core protein in Alzheimer's disease and Down syndrome." <i>Proc. Natl. Acad. Sci. 82, 4245-9</i>	<input type="checkbox"/>
PAO	MILLER DL ET AL. (1994) "Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease." <i>Archives of Biochemistry and Biophysics 301, 41-52</i>	<input type="checkbox"/>
PAO	NASLUND ET AL. (1994) "Relative abundance of Alzheimer A β amyloid peptide variants in Alzheimer disease and normal aging." <i>Proc. Natl. Acad. Sci. USA 91, 8378-8382</i>	<input type="checkbox"/>
PAO	PIKE CJ ET AL. (1995) "Amino-terminal deletions enhance aggregation of β -amyloid peptides in vitro." <i>J Biol Chem 270, 23895-8</i>	
PAO	SEUBERT ET AL. (1992) "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids." <i>Nature 359, 325-327</i>	
PAO	VIGO-PELFREY C ET AL. (1993) "Characterization of beta-amyloid peptide from human cerebrospinal fluid." <i>Neurochem 61, 1965-8</i>	

RECEIVED
MAY 20 2002
TC 1700

Examiner Signature	PATRICIA A. DUFFY	Date Considered	4-20-03
--------------------	-------------------	-----------------	---------

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.